Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Friday. Navidea Biopharmaceuticals has a one year low of $0.00 and a one year high of $0.10. The stock has a market cap of $100,084.00, a P/E ratio of -0.02 and a beta of 1.47.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.